Clinical trial
A Study to Investigate Efficacy and Safety of NNC0194-0499 Versus Placebo, Both Administered Alone or in Combination With Semaglutide in People With Type 1 Diabetes
NCT07087795 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study to Investigate Efficacy and Safety of NNC0194-0499 Versus Placebo, Both Administered Alone or in Combination With Semaglutide in People With Type 1 Diabetes
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- July 1, 2025
- Completion date
- September 25, 2026
- Enrollment
- 96 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.